Allotex Accelerates into Commercial Phase and Appoints Michael Mrochen as New CEO

Allotex, which has developed the first natural, human collagen-based eye implant designed to help people over 40 restore their near vision, announced progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and Australia, the company is actively executing a controlled market launch and preparing for expansion into additional regions. Regulatory efforts are progressing, including plans to submit an investigational device exemption (IDE) in the United States in the second quarter of 2025 to develop further market access.

The Allotex implant is placed just beneath the surface of the eye in an outpatient procedure that takes about 10 minutes. Made from natural human collagen—not synthetic material—the implant is flexible, meaning it can be adjusted or removed if needed.

To lead this next phase of commercial growth, Michael Mrochen, PhD, has been appointed as Chief Executive Officer. Dr. Mrochen is a co-founder of Allotex and a globally recognized innovator in ophthalmology.

“I’m honored to lead Allotex as we bring this breakthrough technology to more people,” said Dr. Mrochen. “Our platform restores vision naturally—without glasses, without invasive surgery, and without compromising future treatment options.”

Dr. David Muller, who has served as CEO since Allotex’s founding, is supporting the planned transition and will remain with the company as Scientific Advisor.